Bluejay Diagnostics, Inc. (BJDX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Bluejay Diagnostics, Inc. is a medical diagnostics company developing the "Symphony" platform, a rapid whole-blood testing system for critical care settings. The company's primary product candidate is the Symphony IL-6 test for sepsis monitoring. The company is currently in the pre-revenue stage, focusing on cartridge redevelopment and clinical trials (SYMON-II) with a target FDA 510(k) submission in 2027.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(1,956,604) | $(3,821,039) | $(4,803,845) |
| Operating Expenses | $1,985,361 | $3,874,278 | $4,323,365 |
| Cash and Equivalents (End of Period) | $4,443,076 (as of June 30, 2025) | ||
| Accumulated Deficit | $(38,489,823) (as of June 30, 2025) | ||
| Net Cash Used in Operating Activities | $(3,238,912) (YTD 2025) | ||
| Net Cash Provided by Financing Activities | $3,380,043 (YTD 2025) |
Material Changes vs. Prior Period
- Reduced Net Loss: The net loss for the six months ended June 30, 2025, decreased by approximately $1.0 million compared to the same period in 2024, primarily due to the elimination of significant interest expense from bridge notes that were repaid in late 2024.
- Capital Raise: In April 2025, the company completed a private placement raising gross proceeds of $3.85 million through the exercise of Class C warrants and the sale of new Class E warrants.
- Expense Management: Research and Development (R&D) expenses decreased by approximately $0.7 million YTD compared to 2024, driven by reduced technology transfer efforts. General and Administrative (G&A) expenses increased slightly due to capital raising efforts and public company reporting costs.
- Headcount Reduction: The company reduced its full-time employee headcount to 5 persons, including the departure of the Chief Technology Officer (CTO) and VP of Operations, to preserve cash.
Outlook, Risks, and Contingencies
- Going Concern Warning: The filing explicitly states that the company's financial position raises substantial doubt about its ability to continue as a going concern. Management estimates current cash resources will fund operations only through the fourth quarter of 2025.
- Capital Requirements: The company estimates a need to raise at least $30 million between Q3 2025 and the end of fiscal 2027 to complete cartridge redevelopment, clinical trials, and FDA submission.
- Operational Delays: Due to cash constraints, the company has slowed clinical trial timelines. The target for FDA 510(k) submission has been pushed to 2027, contingent on securing financing.
- Liquidation Risk: If additional financing is not obtained, the board may be forced to consider liquidation under Chapter 7 bankruptcy, likely resulting in little to no value for common stockholders.
- Key Personnel Loss: The departure of the CTO and VP of Operations has resulted in a loss of institutional knowledge, potentially complicating product redevelopment and regulatory efforts.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "fourth quarter 2025" cash runway estimate given the recent reduction in headcount and expenses.
- Financing Progress: Monitor for announcements regarding the $30 million capital raise required to avoid liquidation or further delays.
- Cartridge Redevelopment: Confirm the status of the third-party contractor engagement for Symphony cartridge redevelopment, which is critical for the 2027 FDA timeline.
- Warrant Dilution: Review the terms of the outstanding Class C and Class E warrants, which represent significant potential dilution to existing shareholders.
- Regulatory Milestones: Track the enrollment and data analysis progress of the SYMON-II pivotal clinical study.